Article Text

Unexpected outcome (positive or negative) including adverse drug reactions
Cyclophosphamide-induced reversible posterior leukoencephalopathy syndrome
  1. Maria Jose Abenza-Abildua1,
  2. Blanca Fuentes1,
  3. Domingo Diaz2,
  4. Aranzazu Royo3,
  5. Teresa Olea4,
  6. Maria Jose Aguilar-Amat1,
  7. Exuperio Diez-Tejedor1
  1. 1
    Hospital Universitario La Paz, Neurology, Paseo de la Castellana 261, Madrid, 28046, Spain
  2. 2
    Hospital Universitario La Paz, Critical Care Unit, Paseo de la Castellana 261, Madrid, 28046, Spain
  3. 3
    Hospital Universitario La Paz, Neuroradiology Section, Paseo de la Castellana 261, Madrid, 28046, Spain
  4. 4
    Hospital Universitario La Paz, Nephrology, Paseo de la Castellana 261, Madrid, Madrid, 28046, Spain
  1. Maria Jose Abenza-Abildua, mariajoaa{at}yahoo.es

Summary

Reversible posterior leukoencephalopathy syndrome (RPLS) is a clinical radiological syndrome, characterised by acute headache, altered consciousness, seizures and hypertension. The most frequent causes are hypertensive encephalopathy, eclampsia and some immunosuppressive therapies. The pathogenesis remains unclear, but it appears to be related to altered cerebral circulation, producing oedema that can be seen on MRI, and it resolves in 2 or 3 weeks. In the present report, a possible first reported case of cyclophosphamide-induced RPLS in a 27-year-old man with high blood pressure (HBP) and glomerulonephritis caused by Goodpasture syndrome, treated with cyclophosphamide during the last month and prednisone for glomerulonephritis resulting from Goodpasture syndrome without other immunosuppressive drugs, is described.

Symptoms appeared during a hypertensive crisis, but when cyclophosphamide was replaced by rituximab and hypertension was controlled, the patient did not have neurological symptoms. Almost all reported cases induced by immunosuppressive therapy or other causes were associated with hypertension as well.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Patient consent: Patient/guardian consent was obtained for publication.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.